Erratum: High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: A phase II study by the GFM (Annals of Hematology DOI: 10.1007/s00277-013-1686-4);High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: A phase II study by the GFM

Annals of Hematology

Volumn 92, Issue 5, 2013, Pages 621-631

  Kelaidi, C ^a   Beyne Rauzy, O ^a   Braun, T ^a   Sapena, R ^a   Cougoul, P ^a   Ades L ^a   Pillard, F ^a   Lambert, C ^a   Charniot, J C ^a   Guerci, A ^a   Choufi, B ^a   Stamatoullas, A ^a   Slama, B ^a   De Renzis, B ^a   Ame, S ^a   Damaj, G ^a   Boyer, F ^a   Chaury, M P ^a   Legros, L ^a   Cheze, S ^a   Testu, A ^a   Gyan, E ^a   Bene M C ^a   Rose, C ^a   Dreyfus, F ^a   Fenaux, P ^a   more..

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

Anemia; Darbepoetin; Exercise capacity; Myelodysplastic syndromes; Quality of life

Indexed keywords

ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG TOLERANCE; EXERCISE; FEMALE; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; INTERNATIONAL PROGNOSTIC SCORE SYSTEM; LOW RISK POPULATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVERALL SURVIVAL; OXYGEN CONSUMPTION; PHASE 2 CLINICAL TRIAL; PHYSICAL PERFORMANCE; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; TREATMENT DURATION; WALKING;

EID: 84877922011     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1713-5     Document Type: Erratum

References (34)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199
2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon
3. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes (see comment) (erratum appears in Blood 1998 Feb 1;91:1100). Blood 89:2079-2088
4. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA (2002) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95:888-895
5. Nilsson-Ehle H, Birgegård G, Samuelsson J, Antunovic P, Astermark J, Garelius H, Engström LM, Kjeldsen L, Nilsson L, Olsson A, Skov-Holm M, Wallvik J, Gulbrandsen N, Hellström-Lindberg E (2011) Quality of life, physical function and MRI T2*in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions. Eur J Haematol 87:244-252
6. Hellstrom-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J, Ost A, Greenberg P (1997) Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 99:344-351
7. Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarré MC, Damaj G, Giraudier S, Guerci A, Laurent G, Dombret H, Chomienne C, Ribrag V, Stamatoullas A, Marie JP, Vekhoff A, Maloisel F, Navarro R, Dreyfus F, Fenaux P (2004) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104:321-327
8. Spiriti MA, Latagliata R, Niscola P, Cortelezzi A, Francesconi M, Ferrari D, Volpe E, Clavio M, Grossi A, Reyes MT, Musto P, Mitra ME, Azzara A, Pagnini D, D'Arena G, Spadano A, Balleari E, Pecorari P, Capochiani E, De Biasi E, Perego D, Monarca B, Pisani F, Scaramella G, Petti MC (2005) Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 84:167-176
9. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, Coiteux V, Leroux G, Lepelley P, Daniel MT, Cheze S, Mahé B, Ferrant A, Ravoet C, Escoffre-Barbe M, Adès L, Vey N, Aljassem L, Stamatoullas A, Mannone L, Dombret H, Bourgeois K, Greenberg P, Fenaux P, Dreyfus F, GFM group Groupe Francophone des Myélodysplasies (2008) Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 111:574-582
10. Jädersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, Pascutto C, Porwit A, Cazzola M, Hellström-Lindberg E (2008) Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 26:3607-3613
11. Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, Paietta E, van der Jagt R, Houston J, Thomas ML, Cella D, Rowe JM (2009) Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the Eastern Cooperative Oncology Group (E1996). Blood 114:2393-2400
12. Stasi R, Abruzzese E, Lanzetta G, Terzoli E, Amadori S (2005) Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 16:1921-1927
13. Musto P, Lanza F, Balleari E, Grossi A, Falcone A, Sanpaolo G, Bodenizza C, Scalzulli PR, La Sala A, Campioni D, Ghio R, Cascavilla N, Carella AM (2005) Darbepoetin alfa for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 128:204-209
14. Giraldo P, Nomdedeu B, Loscertales J, Requena C, de Paz R, Tormo M, Navarro P, Benedit P, Gasquet JA, Aranesp in Myelodysplastic Syndromes (ARM) Study Group (2006) Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer 107:2807-2816
15. Mannone L, Gardin C, Quarre MC, Bernard JF, Vassilieff D, Ades L, Park S, Vaultier S, Hamza F, Beyne-Rauzy MO, Cheze S, Giraudier S, Agape P, Legros L, Voillat L, Dreyfus F, Fenaux P (2006) High-dose darbepoetin alfa in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 133:513-519
16. Gabrilove J, Paquette R, Lyons RM, Mushtaq C, Sekeres MA, Tomita D, Dreiling L (2008) Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 142:379-393
17. Gotlib J, Lavori P, Quesada S, Stein RS, Shahnia S, Greenberg PL (2009) A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. Am J Hematol 84:15-20
18. Oliva EN, Nobile F, Alimena G, Specchia G, Danova M, Rovati B, Ronco F, Impera S, Risitano A, Alati C, Breccia M, Carmosino I, Vincelli I, Latagliata R (2010) Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. Leukemia & Lymphoma 51:1007-1014
19. Villegas A, Arrizabalaga B, Fernández-Lago C, Castro M, Mayans JR, González-Porras JR, Duarte RF, Remacha AF, Luño E, Gasquet JA (2011) Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response. Curr Med Res Opin 27:951-960
20. AFSSAPS (2002) Transfusion de globules rouges homologues: products, indications, alternatives. Recommendations. Agence Française de Sécurité Sanitaire des Produits de Sante, Paris
21. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419-425
22. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D (2012) Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 120:2454-2465
23. Albouaini K, Egred M, Alahmar A, Wright DJ (2007) Cardiopulmonary exercise testing and its application. Heart 93:1285-1292
24. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, Berman LB (1985) The six-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 132:919-923
25. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA, Wallace RB (1994) A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 49:M85-M94
26. Medelli J (1998) Les épreuves d'effort en médecine du sport. Sci Sports 13:174-187
27. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13:63-74
28. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24:547-561
29. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481
30. Peto R, Peto J (1972) Asymptotically efficient rank invariant test procedures. J R Stat Soc A 135:185-198
31. Fine J, Gray R (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509
32. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Löwenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL, World Health Organization (WHO) international working group (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674
33. Kelaidi C, Stamatoullas A, Beyne-Rauzy O, Raffoux E, Quesnel B, Guerci A, Dreyfus F, Brechignac S, Berthou C, Prebet T, Hicheri Y, Hacini M, Delaunay J, Gourin MP, Camo JM, Zerazhi H, Taksin AL, Legros L, Choufi B, Fenaux P, Groupe Francophone des Myélodysplasies (2010) Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies. Haematologica 95:892-899
34. Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V (2009) An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer 115:706-715